Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard bought 31,704 shares of the company’s stock in a transaction dated Friday, October 7th. The stock was purchased at an average price of $4.73 per share, with a total value of $149,959.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.52 on Friday. The firm’s 50-day moving average is $4.89 and its 200-day moving average is $5.90. The company’s market capitalization is $186.21 million. Argos Therapeutics Inc. has a 12-month low of $1.61 and a 12-month high of $13.97.
Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. On average, equities analysts predict that Argos Therapeutics Inc. will post ($1.56) EPS for the current year.
Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in shares of Argos Therapeutics during the second quarter worth about $137,000. California State Teachers Retirement System purchased a new stake in shares of Argos Therapeutics during the second quarter worth about $137,000. KCG Holdings Inc. purchased a new stake in shares of Argos Therapeutics during the second quarter worth about $163,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 33,862 shares during the last quarter. Hedge funds and other institutional investors own 11.05% of the company’s stock.
Several equities analysts have recently commented on the stock. Zacks Investment Research cut shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Monday, June 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Friday, June 17th. Finally, FBR & Co decreased their price target on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $11.50.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.